(Press-News.org) BOSTON – Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists.
Patients in the clinical trial who got the combined therapies also had fewer serious adverse side effects than those who received only ipilimumab, the researchers report in the Journal of the American Medical Association.
The group treated with both ipilimumab and the immune stimulant, called sargramostim, had a one-year survival rate of 68.9 percent vs. 52.9 percent in the ipilimumab-only group. In both groups, however, the median progression-free survival (the length of time before the cancer began to grow) was similar – 3.1 months.
The two drug combination "reveals the possibilities of combining an immune signaling molecule with taking the brakes off at the same time," said F. Stephen Hodi, MD, first author on the clinical trial report. Hodi is director of the Melanoma Treatment Center and director of the Center for Immuno-Oncology at Dana-Farber.
Ipilimumab, sold as Yervoy, is an immunotherapy drug consisting of a monoclonal antibody that targets a protein receptor, CTLA-4. Because CTLA-4 acts like a brake on the immune system, it prevents the body's defenses from attacking cancer cells. By blocking CTLA-4, ipilimumab releases the brake, allowing cell-killing T cells to assault the cancer cells. It is sold for treatment of melanoma and is in clinical trials for lung and other cancers.
Sargramostim is a form of GM-CSF (granulocyte-macrophage colony-stimulating factor), a natural protein that spurs the growth of white blood cells in the immune system. It is used, among other things, to restore white blood cells following a stem cell transplant for cancer.
Hodi designed this investigator-initiated clinical trial to find out if giving sargramostim along with ipilimumab would have a synergistic effect against the melanoma – like pressing the immune system's accelerator while releasing the brake. He had reason to think so, because clinical benefits had been seen in cancer patients who received ipilimumab along with cancer vaccines that pumped out GM-CSF.
The phase 2 randomized clinical trial was conducted by the Eastern Cooperative Oncology Group, enrolling 245 patients with stage 3 or stage 4 metastatic melanoma who had been treated with other drugs. The patients were followed for a median of 13.3 months.
The advantage in overall survival of nearly five months in the group receiving sargramostim was significant, as was the lower toxicity in that group. Why the drug combination did not prolong the time before the disease progress – as might be expected, because it did extend overall survival – is not clear, the researchers said. "It could be that the treatment is causing inflammation that that looked like early disease progression, but we won't know without further studies," Hodi said.
Larger trials and longer follow-up will be needed to confirm the results, he added. "But this opens the possibility of improving clinical outcomes and decreasing serious side effects in treating advanced melanoma with ipilimumab."
INFORMATION:
Senior author of the paper is John M. Kirkwood, MD, of the University of Pittsburgh Cancer Institute. Other authors are from Dana-Farber, Beth Israel Deaconess Medical Center, the University of Pittsburgh, the Christ Hospital, Cincinnati, and Vanderbilt University.
The research was supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA80775, CA39229, CA49957, and CA32291 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, is world renowned for its leadership in adult and pediatric cancer treatment and research. Designated as a comprehensive cancer center by the National Cancer Institute (NCI), it is one of the largest recipients among independent hospitals of NCI and National Institutes of Health grant funding. For more information, go to http://www.dana-farber.org.
Immune booster combined with checkpoint blocker improves survival in metastatic melanoma
2014-11-04
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Long-acting anti-meth treatment demonstrates protective benefits for meth addiction
2014-11-04
San Diego — A recently developed Adeno-Associated Virus (AAV)-based medication has the potential to offer substantial protective effects for patients attempting to cease methamphetamine use. This research is being presented at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Diego, Nov. 2-6.
Methamphetamine, commonly referred to as meth, is an addictive substance that can cause brain damage, organ failure, stroke, open sores, rotting teeth, mania, paranoia, ...
Novel nanofiber-based technology could help prevent HIV/AIDS transmission
2014-11-04
San Diego — Scientists have developed a novel topical microbicide loaded with hyaluronic acid (HA) nanofibers that could potentially prevent transmission of the human immunodeficiency virus (HIV) through the vaginal mucosa. This research is being presented at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Diego, Nov. 2-6.
HIV is an infectious virus that attacks T lymphocytes, a type of white blood cell that prevents infections and disease. Over time, HIV ...
Medicare may need to expand options for behavioral weight loss counseling in primary care
2014-11-04
PHILADELPHIA – An important addition to the "eat less, move more" strategy for weight loss lies in behavioral counseling to achieve these goals. But research on how primary care practitioners can best provide behavioral weight loss counseling to obese patients in their practices — as encouraged by the Centers for Medicare and Medicaid Services (CMS) — remains slim, according to a systematic review of this topic published today in JAMA. The study was led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
"After an ...
Autism spectrum disorder: 10 tips guidance article
2014-11-04
Washington D.C., November 4, 2014 – A Clinical Perspectives article published in the November 2014 issue of the Journal of the American Academy of Child and Adolescent Psychiatry proposes a tool to empower stakeholders, guide caregivers, and provide a rationale for advocates, when considering the systems of support offered to people with an autism spectrum disorder (ASD).
Organizations such as the American Academy of Child and Adolescent Psychiatry, the European Society for Child and Adolescent Psychiatry, the International Association for Child and Adolescent Psychiatry ...
NASA's SDO sees a mid-level solar flare: Nov. 3
2014-11-04
The sun emitted a mid-level solar flare, peaking at 5:40 p.m. EST on Nov. 3, 2014. NASA's Solar Dynamics Observatory, which watches the sun constantly, captured an image of the event. Solar flares are powerful bursts of radiation. Harmful radiation from a flare cannot pass through Earth's atmosphere to physically affect humans on the ground, however -- when intense enough -- they can disturb the atmosphere in the layer where GPS and communications signals travel.
To see how this event may affect Earth, please visit NOAA's Space Weather Prediction Center at http://spaceweather.gov, ...
When less is more: Death in moderation boosts population density in nature
2014-11-04
In nature, the right amount of death at the right time might actually help boost a species' population density, according to new research that could help in understanding animal populations, pest control and managing fish and wildlife stocks.
In a paper in the journal Trends in Ecology and Evolution, a Princeton University researcher and European colleagues conclude that the kind of positive population effect an overall species experiences from a loss of individuals, or mortality, depends on the size and developmental stage of the creatures that die.
If many juveniles ...
Brain changes linked to prematurity may explain risk of neurodevelopmental disorders
2014-11-04
Disturbances in the early stages of brain growth, such as preterm birth – when many of the brain's structures have not yet fully developed – appears to affect the brain's neuro-circuitry, which may explain premature babies' higher risk of neurodevelopmental disorders including ADHD and autism spectrum disorder.
Researchers led by Natasha Lepore, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, have located significant alterations to specific surface regions of the brain. Described in a study published online this week by the journal ...
High-speed 'label-free' imaging could reveal dangerous plaques
2014-11-04
WEST LAFAYETTE, Ind. – Researchers are close to commercializing a new type of medical imaging technology that could diagnose cardiovascular disease by measuring ultrasound signals from molecules exposed to a fast-pulsing laser.
The system takes precise three-dimensional images of plaques lining arteries and identifies deposits that are likely to rupture and cause heart attacks, said Ji-Xin Cheng (pronounced Jee-Shin), a professor in Purdue University's Weldon School of Biomedical Engineering and Department of Chemistry.
The imaging reveals the presence of carbon-hydrogen ...
Hot flushes are going unrecognized, leaving women vulnerable
2014-11-04
Hot flushes are one of the most distressing conditions faced by women who have been treated for breast cancer, but they are not being adequately addressed by healthcare professionals and some women consider giving up their post cancer medication to try and stop them, a new study has shown.
More than 70 per cent of women who have had breast cancer experience menopausal problems, and hot flushes in particular, which are among the most prevalent and potentially distressing problems following breast cancer treatment. These can also be long lasting, persisting for more than ...
How cells defend themselves against antibiotics and cytostatic agents
2014-11-04
This news release is available in German.
"On the one hand, ABC transporters causes diseases such as cystic fibrosis, while on the other hand they are responsible for the immune system recognising infected cells or cancer cells," explains Professor Robert Tampé from the Institute for Biochemistry at the Goethe University. The considerable medical, industrial and economic significance of ABC transporters is also based on the fact that they cause bacteria and other pathogens to become resistant to antibiotics. Likewise, they can help cancer cells to defend themselves ...